Form 4: Zevra Therapeutics CFO R. LaDuane Clifton Reports Stock Option Grant and RSU Transactions

R. LaDuane Clifton, CFO & Treasurer of Zevra Therapeutics, reports the acquisition of stock options and the vesting/settlement of restricted stock units.

Summary

• On January 30, 2025, R. LaDuane Clifton, CFO & Treasurer of Zevra Therapeutics, was granted stock options to purchase 68,000 shares of common stock at an exercise price of $8.02.
• These options vest in four equal annual installments starting January 29, 2026, and expire on January 29, 2035.
• Also on January 30, 2025, Clifton acquired 34,000 restricted stock units (RSUs) which vest in three annual installments starting January 30, 2026.
• On January 31, 2025, 43,333 previously granted RSUs vested and settled, resulting in the disposition of 43,333 shares of common stock.
• Following these transactions, Clifton directly owns 62,361 shares of common stock, 68,000 stock options, and 34,000 RSUs.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of insider transactions. The grants suggest confidence, but the sale of shares from vested RSUs is a normal part of executive compensation.

Positives

• The grant of stock options and RSUs to the CFO aligns his interests with those of the shareholders.
• The vesting schedules for the options and RSUs incentivize continued service with the company.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities. They provide investors with insights into the actions of company executives and their confidence in the company's future prospects.

Stakeholder Impact

• Shareholders may view the stock option and RSU grants as a positive sign, aligning management's interests with theirs.
• Employees may see the grants as a reflection of the company's commitment to its leadership.

Key Dates